Raloxifene

Drug Profile

Raloxifene

Alternative Names: Celvista; Evista; Keoxifene; LY 139481; LY 156758; Optruma; Sevista (raloxifene)

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Calcium regulators; Osteoporosis therapies; Small molecules; Stilbenes
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Breast cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Fracture; Postmenopausal osteoporosis
  • No development reported Cardiovascular disorders; Endometriosis; Hypercholesterolaemia; Leiomyoma; Vasomotor symptoms

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2014 Authorised generic raloxifene licensed to Prasco Laboratories in USA
  • 04 Mar 2014 First generic equivalent approved for Postmenopausal osteoporosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top